A number of research firms have changed their ratings and price targets for Redhill Biopharma (NASDAQ: RDHL):

  • 10/4/2017 – Redhill Biopharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock, up previously from $33.00.
  • 10/4/2017 – Redhill Biopharma had its “buy” rating reaffirmed by analysts at Roth Capital. They now have a $27.00 price target on the stock.
  • 9/27/2017 – Redhill Biopharma was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “
  • 9/20/2017 – Redhill Biopharma was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “
  • 9/13/2017 – Redhill Biopharma is now covered by analysts at UBS AG. They set a “reduce” rating on the stock.
  • 8/29/2017 – Redhill Biopharma was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “

Shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) opened at 9.90 on Friday. The stock has a 50 day moving average of $8.95 and a 200-day moving average of $9.33. Redhill Biopharma Ltd. has a 52-week low of $8.16 and a 52-week high of $14.74. The firm’s market capitalization is $169.91 million.

Redhill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. Equities analysts expect that Redhill Biopharma Ltd. will post ($2.36) earnings per share for the current fiscal year.

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.